[A05-20C] Bupropion, mirtazapine, and reboxetine in the treatment of depression

Last updated 01.06.2011

Project no.:
A05-20C

Commission:
Commission awarded on 22.02.2005 by the Federal Joint Committee (G-BA).

Report type:
Report

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Mental and emotional wellbeing

24.11.2009

Antidepressants: benefit of reboxetine not proven

However, bupropion XL and mirtazapine can benefit people suffering from depression

24.11.2009

IQWiG calls for compulsory publication of all clinical trials

Manufacturers who conceal data are harming patients and hindering the work of IQWiG and the G-BA

10.06.2009

Preliminary report on antidepressants published

Benefit of bupropion proven – Benefit of reboxetine not proven: manufacturer conceals study data

10.06.2009

Pfizer conceals study data

Drug manufacturer hinders the best possible treatment of patients with depression

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.